News
-
-
-
COMMUNIQUÉ DE PRESSE
MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development
MIRA Pharmaceuticals submits IND application for novel oral ketamine analog Ketamir-2 to FDA, targeting neuropathic pain. Phase I trials planned to start in 2025 -
-
-
COMMUNIQUÉ DE PRESSE
MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End
MIRA Pharmaceuticals successfully completes preclinical safety program for Ketamir-2, paving the way for clinical trials in neuropathic pain. Strategic focus on advancing innovative, safe treatments for patients -
-
-
COMMUNIQUÉ DE PRESSE
MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site
MIRA Pharmaceuticals progresses towards clinical-stage status with Phase I/IIa trial announcement on Ketamir-2, a novel oral ketamine analog, for pain management. CHDR's PainCart technology leveraged -
